HALOZYME THERAPEUTICS INC (HALO) Stock Price, Quote, News and Overview
NASDAQ:HALO - Nasdaq - US40637H1095 - Common Stock
HALO Quote and Key Statistics
HALOZYME THERAPEUTICS INC
NASDAQ:HALO (1/22/2025, 8:00:02 PM)
Premarket: 54.6 -0.68 (-1.23%)55.28
-0.66 (-1.18%)
HALO Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.43% | ||
| ROA | 18.53% | ||
| ROE | 86.69% | ||
| Debt/Equity | 3.32 |
HALO Performance and Technical Analysis
HALO Ownership and Analysts
HALO Latest News and Analysis
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
Don't overlook HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—a stock with solid growth prospects and a reasonable valuation.
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.
BridgeBio Pharma Stock Earns 87 RS Rating
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.
SpringWorks Therapeutics Stock Gets A RS Rating Lift
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.
About HALO
Company Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 373 full-time employees. The company went IPO on 2003-01-30. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. The company also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. The company markets and sells Hylenex recombinant, which is a formulation of rHuPH20. The company markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Company Info
HALOZYME THERAPEUTICS INC
12390 El Camino Real
San Diego CALIFORNIA 92121-1345 US
CEO: Helen I. Torley
Employees: 373
Company Website: https://www.halozyme.com/
Investor Relations: https://ir.halozyme.com/
Phone: 18587948889
HALO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.74 | 299.00B | ||
| AMGN | AMGEN INC | 14.23 | 146.98B | ||
| GILD | GILEAD SCIENCES INC | 21 | 115.95B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839.22 | 110.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.97 | 74.73B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.38B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.75B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.66B | ||
| NTRA | NATERA INC | N/A | 22.70B | ||
| BIIB | BIOGEN INC | 8.74 | 20.80B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.34B |